Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel To Weigh Non-Inferiority Trial Margin In Review Of J&J’s Antibiotic Doribax

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Anti-Infective Drugs Advisory Committee will consider the merits of a 20 percent non-inferiority margin based on clinical response in patients with nosocomial and ventilator-associated pneumonia.

You may also be interested in...



J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA

End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.

J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA

End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.

J&J’s Doribax Is Subject Of FDA’s First "Complete Response" To An NDA

FDA is seeking additional information on Johnson & Johnson's Doribax (doripenem) prior to approving the antibiotic for the treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, the company announced Aug. 21

Related Content

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel